This is a $3,079,369 cost-plus-fixed-fee contract awarded to Bolder Biotechnology Inc., a small disadvantaged business, by the National Institute of Allergy and Infectious Diseases (NIAID) for the advanced development of BBT-059 as a radiation medical countermeasure. The contract supports research and development to create a safe and effective treatment that can mitigate radiation-associated injuries when administered up to 48 hours after exposure. This effort is part of NIAID's broader mission to develop medical countermeasures and biodosimetry approaches to address public health needs related to radiological or nuclear incidents. The contract does not have a set-aside designation. Bolder Biotechnology has previously received other NIAID grants and contracts for related research on medical countermeasures and treatments for radiation exposure, as well as infectious diseases.
Generated 6/28/24, 9:59 AM